市場調査レポート
商品コード
1442276

eCOA (Electronic Clinical Outcome Assessment) ソリューションの世界市場:モダリティ (ウェアラブル・モバイル・BYOD)・タイプ (PRO・CLINRO・OBSRO・PERFO)・用途・エンドユーザー・地域別 - 予測(~2029年)

Electronic Clinical Outcome Assessment (eCOA) Solution Market by Modality (Wearable, Mobile, BYOD), Type (PRO, CLINRO, OBSRO, PERFO), Use, End User, and Region - Global Forecast to 2029

出版日: | 発行: MarketsandMarkets | ページ情報: 英文 413 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=160.10円
eCOA (Electronic Clinical Outcome Assessment) ソリューションの世界市場:モダリティ (ウェアラブル・モバイル・BYOD)・タイプ (PRO・CLINRO・OBSRO・PERFO)・用途・エンドユーザー・地域別 - 予測(~2029年)
出版日: 2024年02月20日
発行: MarketsandMarkets
ページ情報: 英文 413 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界のeCOA (Electronic Clinical Outcome Assessment) ソリューションの市場規模は、2024年の18億米ドルから、予測期間中に16.6%のCAGRで推移し、2029年には39億米ドルの規模に成長すると予測されています。

デジタルデータ収集・分析への傾向の高まり、経済的なデータ収集ソリューションへのニーズの高まり、医療機関におけるコネクテッドデバイスの統合の進展といった要因が同市場の成長を促進しています。一方、データ漏洩、不正アクセス、サイバーセキュリティの脅威に対する懸念が予測期間中のeCOAソリューションの採用をある一定程度妨げる可能性があります。

調査範囲
調査対象年 2022-2029年
基準年 2022年
予測期間 2024-2029年
検討単位 金額 (米ドル)
セグメント コンポーネント・製品タイプ・展開モデル・用途・エンドユーザー・地域
対象地域 北米・欧州・アジア太平洋・ラテンアメリカ・中東&アフリカ

デバイスタイプ別では、BYOD (Bring Your Own Device) モデルの部門が予測期間中に最大のシェアを示すと予測されています。専用デバイスの管理の必要がなくなり、試験コストを削減できるため、費用対効果が高いことから、BYODの採用が拡大しています。患者が自分のデバイスに慣れ親しむことで、使い勝手が向上し、エンゲージメントとデータ品質も向上します。また、地理的に分散し、リソースが限られている患者のアクセシビリティを向上させ、分散型試験と整合させられます。さらに、安全なデータ暗号化の技術的進歩がセキュリティ上の懸念を払拭し、進化する規制が特定地域での安全なBYODの導入を支持するため、BYODによるeCOAは臨床試験におけるコスト効率の高い患者中心のアプローチとして位置付けられています。

用途別では、臨床試験の部門が予測期間中の最大のシェアを示すと予測されています。臨床試験におけるeCOAの利用は、リアルタイムの取り込みと転記ミスの最小化によって達成されるデータ品質の向上、ユーザーフレンドリーなプラットフォームとデータ所有の向上によって促進される患者エンゲージメントの強化、データ収集の合理化と分析の迅速化による試験効率の向上など、多くの利点によって推進されています。より質の高い研究、患者満足度の向上、迅速なR&Dが実現するため、eCOAは臨床研究において、より効率的で患者中心の未来に向けた新たなゴールドスタンダードとして位置づけられています。

当レポートでは、世界のeCOA (Electronic Clinical Outcome Assessment) ソリューションの市場を調査し、市場概要、市場影響因子および市場機会の分析、技術・特許の動向、法規制環境、ケーススタディ、市場規模の推移・予測、各種区分・地域別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • 市場力学
    • 市場力学:影響分析
    • 促進要因
    • 抑制要因
    • 機会
    • 課題

第6章 産業考察

  • 主要な業界動向の概要
  • 価値/サプライチェーン分析
  • エコシステム分析
  • 技術分析
  • 規制状況
  • ポーターのファイブフォース分析
  • 価格分析
  • ケーススタディ分析
  • 特許分析
  • 主な会議とイベント
  • 顧客のビジネスに影響を与える動向/ディスラプション
  • 主なステークホルダーと購入基準
  • エンドユーザー分析
  • 収益モデル分析
  • 投資の情勢

第7章 eCOA (Electronic Clinical Outcome Assessment) ソリューション市場:コンポーネント別

  • ソフトウェア
  • サービス
  • ウェアラブル、モバイルデバイス、その他のデバイス
    • BYOD (BRING YOUR OWN DEVICE) モデル
    • プロビジョンドデバイスモデル
    • ハイブリッドモデル

第8章 eCOA (Electronic Clinical Outcome Assessment) ソリューション市場:製品別

  • ePRO (ELECTRONIC PATIENT-REPORTED OUTCOMES)
  • eOBSRO (ELECTRONIC PATIENT-REPORTED OUTCOMES)
  • eCLINRO (ELECTRONIC OBSERVER-REPORTED OUTCOMES)
  • ePERFO (ELECTRONIC PERFORMANCE-REPORTED OUTCOME)

第9章 eCOA (Electronic Clinical Outcome Assessment) ソリューション市場:展開モデル別

  • オンプレミスモデル
  • ウェブホストおよびクラウドベースモデル
  • ハイブリッドモデル

第10章 eCOA (Electronic Clinical Outcome Assessment) ソリューション市場:用途別

  • 臨床試験
    • 腫瘍
    • 感染症
    • 神経
    • 代謝異常症
    • 免疫
    • 心血管疾患
    • 希少疾患・遺伝性疾患
    • 精神的健康障害
    • その他
  • 観察研究とRWEの生成
  • 患者管理と登録
  • その他

第11章 eCOA (Electronic Clinical Outcome Assessment) ソリューション市場:エンドユーザー別

  • 製薬およびバイオテクノロジー会社
  • 委託研究機関 (CROS)
  • 政府機関
  • メッドテック企業
  • 病院および医療提供者
  • 学術研究機関
  • コンサルティングサービス会社

第12章 eCOA (Electronic Clinical Outcome Assessment) ソリューション市場:地域別

  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ

第13章 競合情勢

  • 概要
  • 主要企業の戦略/有力企業
  • 収益分析
  • 市場シェア分析
  • ブランド/ソフトウェアの比較分析
  • eCOAソリューションベンダーの評価と財務指標
  • 企業評価マトリックス:主要企業
  • 企業評価マトリックス:スタートアップ/中小企業
  • 競合シナリオ

第14章 企業プロファイル

  • 主要企業
    • MEDIDATA (A DASSAULT SYSTEMES COMPANY)
    • IQVIA
    • SIGNANT HEALTH
    • CLARIO
    • ICON PLC
    • ORACLE CORPORATION
    • MEDABLE INC.
    • MERATIVE L.P.
    • PAREXEL INTERNATIONAL (MA) CORPORATION
    • CLIMEDO HEALTH GMBH
    • HEALTHENTIA
    • VEEVA SYSTEMS
    • ASSISTEK
    • CUREBASE INC.
    • CASTOR
    • EVIDENTIQ GROUP GMBH
    • YPRIME, LLC
    • CLINICAL INK
    • CLINION
    • KAYENTIS
  • その他の企業
    • TRANSPERFECT
    • OBVIOHEALTH USA, INC.
    • WCG CLINICAL
    • CLINCAPTURE
    • CLOUDBYZ

第15章 付録

目次
Product Code: HIT 8947

The electronic clinical outcome assessment (eCOA) solutions market is projected to reach USD 3.9 billion by 2029 from USD 1.8 billion in 2024, at a CAGR 16.6% during the forecast period. The the growing inclination towards digital data collection and analysis, an escalating need for economical data collection solutions, and the increasing integration of connected devices in healthcare institutions are the factors that will drive the growth of this market. On the other hand, the sensitivity of patient health data requires robust security measures. Concerns about data breaches, unauthorized access, or cybersecurity threats may impede the adoption of eCOA solutions to a certain extent over the forecast period.

Scope of the Report
Years Considered for the Study2022-2029
Base Year2022
Forecast Period2024-2029
Units ConsideredValue (USD) Billion
SegmentsComponent, Product Type, Deployment Model, Application Area, End User, Region
Regions coveredNorth America, Europe, APAC, Latin America, and Middle East Africa

"The BYOD (bring your own device) model segment is estimated to hold the major share in 2023, by type of wearable, mobile and other devices."

The wearable, mobile and other devices market is bifurcated into BYOD (bring your own device) model, provisioned device model, and hybrid model. The BYOD model segment accounted for the largest market share during the forecast period. The growth of BYOD (Bring Your Own Device) adoption is driven by cost-effectiveness, as it eliminates the need for sponsors to manage dedicated devices, lowering trial costs. Patient familiarity with their own devices enhances user-friendliness, boosting engagement and data quality, while increasing accessibility for geographically dispersed and resource-limited patients, aligning with decentralized trials. Additionally, technological advancements in secure data encryption address security concerns, and evolving regulations favor secure BYOD implementation in certain regions, positioning it as a cost-efficient, patient-centric approach in clinical trials.

"Clinical trials segment is estimated to hold the largest share of electronic clinical outcome assessment (eCOA) solutions market, by application."

Based on application, the Electronic Clinical Outcome Assessment (eCOA) Solutions market is segmented into clinical trials, observational studies and real-world evidence (RWE) generation, patient management and registries, and other applications. The clinical trials segment is expected to hold the largest share during the forecast period. The rise of eCOA (Electronic Clinical Outcome Assessment) in clinical trials is driven by a myriad of advantages: heightened data quality achieved through real-time capture and minimized transcription errors, enhanced patient engagement facilitated by user-friendly platforms and improved data ownership, and increased trial efficiency through streamlined data collection and accelerated analysis. This results in superior-quality studies, increased patient satisfaction, and expedited drug development, positioning eCOA as the emerging gold standard for a more efficient, patient-centric future in clinical research.

"Electronic Observer-Reported Outcomes (EOBSRO) segment is expected to register highest growth in the forecast period, by product type segment."

Based on product type, the Electronic Clinical Outcome Assessment (eCOA) Solutions market is segmented into electronic patient-reported outcomes (EPRO), Electronic Clinician-reported outcomes (ECLINRO), electronic observer-reported outcomes (EOBSRO), and Electronic performance-reported outcomes (EPERFO). In 2023, the electronic observer-reported outcomes (EOBSRO) segment segment is expected to register highest growth in the forecast period. Observer-reported outcomes (ObsRO) play a crucial role in gathering real-world evidence outside controlled trial settings, informing post-market research and regulatory decisions. Effective patient monitoring in decentralized trials, improved data quality, availability of holistic picture of patient experience and treatment response are some of the factors that contribute to the growth of the segment.

"Asia Pacific to register the highest growth in the electronic clinical outcome assessment (eCOA) solutions market in the forecast period."

The global electronic clinical outcome assessment (eCOA) solutions market is segmented into four major regions, namely, North America, Europe, APAC, and the Rest of the World. In 2022, Asia Pacific was expected to register the highest growth for electronic clinical outcome assessment (eCOA) solutions systems in the forecast period. Factors such as increasing healthcare expenditure, developing healthcare infrastructure, rising demand for digital solutions in healthcare sector, large patient population, increasing focus on patient-centric care and the need for better data collection and analysis are expected to drive the growth of the electronic clinical outcome assessment (eCOA) solutions market in the Asia Pacific.

Breakdown of the supply-side, demand side, primary interviews by company type, designation, and region:

  • By Supply Side: Tier 1 (31%), Tier 2 (28%), and Tier 3 (41%)
  • By Demand Side: Hospital Directors/VPs/Managers/Department Heads (40%), Pharma & Biopharma Company's Product managers, Purchase Heads, etc. (35%), and Others (25%).
  • By Designation: C-level Executives (31%), Director-level (25%), and Managers (44%)
  • By Region: North America (45%), Europe (20%), Asia Pacific (28%), and RoW (4%)

The prominent players in this market are Koninklijke Signant Health (US), IQVIA Holdings, Inc. (US), Oracle (US), Clario (US), Medable Inc. (US), Medidata (US), Merative (US), ICON plc (Ireland), Paraxel International (MA) Corporation (US), Climedo Health GmbH (Germany), Healthentia (Belgium), Veeva Systems (US), assisTek (US), Curebase Inc. (US), Castor (US), EvidentIQ Group GmbH (Germany), YPrime, LLC. (US), Clinical ink (US), Clinion (US), Kayentis (France), TransPerfect (US), ObvioHealth USA, Inc. (US), WCG Clinical (Germany), ClinCapture (US), and Cloudbyz (US). Players adopted organic as well as inorganic growth strategies such as product launches and enhancements, and investments, partnerships, collaborations, joint ventures, funding, acquisition, expansions, agreements, sales contracts, and alliances to increase their offerings, cater to the unmet needs of customers, increase their profitability, and expand their presence in the global market.

Research Coverage

  • The report studies the electronic clinical outcome assessment (eCOA) solutions market based on component, product type, deployment model, application area, end user, and region.
  • The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth.
  • The report evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders.
  • The report studies micro-markets with respect to their growth trends, prospects, and contributions to the total electronic clinical outcome assessment (eCOA) solutions market.
  • The report forecasts the revenue of market segments with respect to five major regions.

Reasons to Buy the Report

The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or a combination of the below-mentioned five strategies.

This report provides insights into the following pointers:

  • Analysis of key drivers (increasing R&D expenditure for product development by medtech, and pharma-biotech companies, rising operational costs and regulatory requirements associated with clinical research studies, favorable government support and funding for clinical trials, growing prevalence of chronic diseases & subsequent increase in clinical trials, effective monitoring of clinical data, reduction in overall costs and timelines of clinical trials), restraints (lack of skilled professionals to develop and operate eCOA solutions, high implementation and maintenance cost, lack of awareness about eCOA solutions among end users), opportunities (surging eCOA adoption owing to increasing number of clinical trials in emerging economies, growing outsourcing of clinical trial processes to CROs, gradual shift from manual data interpretation to real-time data analysis, growing penetration of mobile technology in healthcare industry), and challenges (evolving regulatory landscape and compliance requirements, interoperability & integration, data security & privacy issues, resistance from traditional healthcare professionals and concerns regarding software reliability) influencing the growth of electronic clinical outcome assessment (eCOA) solutions market.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the electronic clinical outcome assessment (eCOA) solutions market.
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of electronic clinical outcome assessment (eCOA) solutions solutions across regions.
  • Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the electronic clinical outcome assessment (eCOA) solutions market.
  • Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the electronic clinical outcome assessment (eCOA) solutions market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKET SEGMENTATION
    • FIGURE 1 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET SEGMENTATION
    • 1.3.2 REGIONAL SCOPE
  • 1.4 YEARS CONSIDERED
    • 1.4.1 CURRENCY CONSIDERED
    • TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD
  • 1.5 STAKEHOLDERS
  • 1.6 RECESSION IMPACT

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 2 RESEARCH DESIGN
  • 2.2 SECONDARY SOURCES
    • 2.2.1 KEY DATA FROM SECONDARY SOURCES
  • 2.3 PRIMARY DATA
    • 2.3.1 PRIMARY SOURCES
      • 2.3.1.1 Key data from primary sources
      • 2.3.1.2 Key industry insights
    • 2.3.2 BREAKDOWN OF PRIMARY INTERVIEWS
    • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY CATEGORY, DESIGNATION, AND REGION
  • 2.4 RESEARCH METHODOLOGY DESIGN
    • FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
  • 2.5 MARKET SIZE ESTIMATION
    • FIGURE 5 SUPPLY-SIDE MARKET ESTIMATION: REVENUE SHARE ANALYSIS
    • 2.5.1 BOTTOM-UP APPROACH
    • FIGURE 6 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: BOTTOM-UP APPROACH
    • FIGURE 7 DEMAND-SIDE APPROACH: END-USER SPENDING ON ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS
    • 2.5.2 TOP-DOWN APPROACH
    • FIGURE 8 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: TOP-DOWN APPROACH
    • TABLE 2 FACTOR ANALYSIS
    • FIGURE 9 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • FIGURE 10 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • 2.6 MARKET BREAKDOWN & DATA TRIANGULATION
    • FIGURE 11 DATA TRIANGULATION METHODOLOGY
  • 2.7 ASSUMPTIONS
    • 2.7.1 MARKET SIZING ASSUMPTIONS
    • 2.7.2 OVERALL STUDY ASSUMPTIONS
  • 2.8 LIMITATIONS
    • 2.8.1 SCOPE-RELATED LIMITATIONS
    • 2.8.2 METHODOLOGY-RELATED LIMITATIONS
  • 2.9 RISK ASSESSMENT
    • TABLE 3 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: RISK ASSESSMENT
  • 2.10 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: RECESSION IMPACT ANALYSIS
    • TABLE 4 GLOBAL INFLATION RATE PROJECTIONS, 2021-2028 (% GROWTH)
    • TABLE 5 US HEALTH EXPENDITURE, 2019-2022 (USD MILLION)
    • TABLE 6 US HEALTH EXPENDITURE, 2023-2030 (USD MILLION)

3 EXECUTIVE SUMMARY

    • FIGURE 12 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2024 VS. 2029 (USD MILLION)
    • FIGURE 13 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2024 VS. 2029 (USD MILLION)
    • FIGURE 14 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION)
    • FIGURE 15 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2024 VS. 2029 (USD MILLION)
    • FIGURE 16 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
    • FIGURE 17 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2024 VS. 2029 (USD MILLION)
    • FIGURE 18 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
    • FIGURE 19 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: GEOGRAPHIC SNAPSHOT

4 PREMIUM INSIGHTS

  • 4.1 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET OVERVIEW
    • FIGURE 20 GOVERNMENT INITIATIVES & SURGING R&D EXPENDITURES TO DRIVE MARKET GROWTH
  • 4.2 ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT AND COUNTRY (2023)
    • FIGURE 21 JAPAN ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2023
  • 4.3 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 22 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • 4.4 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: REGIONAL MIX (2021-2029)
    • FIGURE 23 NORTH AMERICA TO CONTINUE TO DOMINATE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET DURING FORECAST PERIOD
  • 4.5 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: DEVELOPED VS. EMERGING ECONOMIES
    • FIGURE 24 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 25 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 MARKET DYNAMICS: IMPACT ANALYSIS
    • 5.2.2 DRIVERS
      • 5.2.2.1 Increasing R&D expenditure for product development by medtech and pharma-biotech companies
    • FIGURE 26 INCREASE IN GLOBAL PHARMACEUTICAL R&D SPENDING, 2014-2028
      • 5.2.2.2 Rising operational costs and regulatory requirements associated with clinical research studies
      • 5.2.2.3 Favorable government support and funding for clinical trials
      • 5.2.2.4 Growing prevalence of chronic diseases & subsequent increase in clinical trials
      • 5.2.2.5 Effective monitoring of clinical data
      • 5.2.2.6 Reduction in overall costs and timelines of clinical trials
    • 5.2.3 RESTRAINTS
      • 5.2.3.1 Dearth of skilled professionals to develop and operate eCOA solutions
      • 5.2.3.2 High implementation and maintenance costs
      • 5.2.3.3 Lack of awareness about eCOA solutions among end users
    • 5.2.4 OPPORTUNITIES
      • 5.2.4.1 Surging eCOA adoption owing to increasing number of clinical trials in emerging economies
      • 5.2.4.2 Growing outsourcing of clinical trial processes to CROs
      • 5.2.4.3 Gradual shift from manual data interpretation to real-time data analysis
      • 5.2.4.4 Growing penetration of mobile technology in healthcare industry
    • 5.2.5 CHALLENGES
      • 5.2.5.1 Evolving regulatory landscape and compliance requirements
      • 5.2.5.2 Concerns regarding data security & privacy
      • 5.2.5.3 Lack of interoperability & integration
      • 5.2.5.4 Resistance from traditional healthcare professionals and concerns regarding software reliability

6 INDUSTRY INSIGHTS

  • 6.1 INTRODUCTION
  • 6.2 OVERVIEW OF KEY INDUSTRY TRENDS
    • 6.2.1 RISING NUMBER OF DECENTRALIZED CLINICAL TRIALS
    • 6.2.2 INCREASED FOCUS ON REAL-WORLD DATA (RWD)
  • 6.3 VALUE/SUPPLY CHAIN ANALYSIS
    • FIGURE 27 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: VALUE CHAIN ANALYSIS (2023)
  • 6.4 ECOSYSTEM ANALYSIS
    • FIGURE 28 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: ECOSYSTEM ANALYSIS (2023)
  • 6.5 TECHNOLOGY ANALYSIS
    • 6.5.1 KEY TECHNOLOGIES
      • 6.5.1.1 Machine learning
      • 6.5.1.2 Artificial intelligence
      • 6.5.1.3 Internet of things
      • 6.5.1.4 Integrated APIs
    • 6.5.2 COMPLEMENTARY TECHNOLOGIES
      • 6.5.2.1 Interactive Voice Response (IVR)
      • 6.5.2.2 Data analytics
      • 6.5.2.3 Telehealth
    • 6.5.3 ADJACENT TECHNOLOGIES
      • 6.5.3.1 Cloud computing
      • 6.5.3.2 Blockchain
  • 6.6 REGULATORY LANDSCAPE
    • 6.6.1 REGULATORY ANALYSIS
      • 6.6.1.1 North America
      • 6.6.1.2 Europe
      • 6.6.1.3 Asia Pacific
      • 6.6.1.4 Latin America
      • 6.6.1.5 Middle East & Africa
    • 6.6.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 7 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 8 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 9 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 10 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 6.7 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 11 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 6.7.1 COMPETITIVE RIVALRY
    • 6.7.2 BARGAINING POWER OF BUYERS
    • 6.7.3 BARGAINING POWER OF SUPPLIERS
    • 6.7.4 THREAT OF SUBSTITUTES
    • 6.7.5 THREAT OF NEW ENTRANTS
  • 6.8 PRICING ANALYSIS
    • 6.8.1 AVERAGE SELLING PRICE TREND, BY REGION
    • 6.8.2 INDICATIVE PRICING ANALYSIS, BY PRODUCT
    • TABLE 12 AVERAGE SELLING PRICE OF ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS, BY SOLUTION TYPE (2023)
  • 6.9 CASE STUDY ANALYSIS
    • 6.9.1 CASE 1: A LEADING ACADEMIC MEDICAL CENTER MONITORS NEWLY DIAGNOSED MYELOMA PATIENTS WITH MEDIDATA ECOA
    • 6.9.2 CASE 2: SIGNANT'S SCALE MANAGEMENT EXPERTISE FACILITATES ENDPOINT ACCURACY & RELIABILITY IN PSORIATIC ARTHRITIS TRIAL
  • 6.10 PATENT ANALYSIS
    • FIGURE 29 TOP PATENT OWNERS AND APPLICANTS FOR ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS (JANUARY 2011-JANUARY 2024)
    • FIGURE 30 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: PATENT ANALYSIS (JANUARY 2011-JANUARY 2024)
    • FIGURE 31 TOP APPLICANT COUNTRIES/REGIONS FOR ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTION PATENTS (JANUARY 2011-JANUARY 2024)
    • TABLE 13 LIST OF PATENTS/PATENT APPLICATIONS IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, 2021-2023
  • 6.11 KEY CONFERENCES & EVENTS, 2023-2024
    • TABLE 14 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: DETAILED LIST OF CONFERENCES & EVENTS
  • 6.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
    • FIGURE 32 REVENUE SHIFT IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET
  • 6.13 KEY STAKEHOLDERS & BUYING CRITERIA
    • 6.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 33 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP 3 END USERS
    • TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE END USERS
    • 6.13.2 BUYING CRITERIA
    • FIGURE 34 KEY BUYING CRITERIA FOR END USERS
    • TABLE 16 KEY BUYING CRITERIA FOR END USERS
  • 6.14 END-USER ANALYSIS
    • 6.14.1 UNMET NEEDS
    • TABLE 17 UNMET NEEDS IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET
    • 6.14.2 END-USER EXPECTATIONS
    • TABLE 18 END-USER EXPECTATIONS IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET
  • 6.15 REVENUE MODEL ANALYSIS
    • 6.15.1 SUBSCRIPTION-BASED MODEL
    • 6.15.2 PAY-PER-STUDY MODEL
    • 6.15.3 CUSTOMIZED SOLUTIONS MODEL
    • 6.15.4 SOFTWARE-AS-A-SERVICE (SAAS) MODEL
    • 6.15.5 CONSULTING AND INTEGRATION SERVICES MODEL
  • 6.16 INVESTMENT LANDSCAPE
    • FIGURE 35 RECENT INVESTMENTS IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET

7 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT

  • 7.1 INTRODUCTION
    • TABLE 19 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION)
    • TABLE 20 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION)
  • 7.2 SOFTWARE
    • 7.2.1 ADVANTAGES OF ECOA SOFTWARE LIKE REAL-TIME ANALYSIS AND STREAMLINED DATA COLLECTION TO FOSTER MARKET GROWTH
    • TABLE 21 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR SOFTWARE, BY COUNTRY, 2018-2022 (USD MILLION)
    • TABLE 22 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR SOFTWARE, BY COUNTRY, 2023-2029 (USD MILLION)
  • 7.3 SERVICES
    • 7.3.1 ABILITY OF ECOA SERVICES TO REDUCE TIME AND COST OF CLINICAL TRIAL PROCESSES TO BOOST DEMAND
    • TABLE 23 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR SERVICES, BY COUNTRY, 2018-2022 (USD MILLION)
    • TABLE 24 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR SERVICES, BY COUNTRY, 2023-2029 (USD MILLION)
  • 7.4 WEARABLES, MOBILE DEVICES, AND OTHER DEVICES
    • TABLE 25 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2018-2022 (USD MILLION)
    • TABLE 26 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2023-2029 (USD MILLION)
    • TABLE 27 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY COUNTRY, 2018-2022 (USD MILLION)
    • TABLE 28 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY COUNTRY, 2023-2029 (USD MILLION)
    • 7.4.1 BRING YOUR OWN DEVICE (BYOD) MODEL
      • 7.4.1.1 Ability of BYOD models to increase flexibility and convenience to drive adoption
    • TABLE 29 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR BRING YOUR OWN DEVICE (BYOD) MODELS, BY COUNTRY, 2018-2022 (USD MILLION)
    • TABLE 30 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR BRING YOUR OWN DEVICE (BYOD) MODELS, BY COUNTRY, 2023-2029 (USD MILLION)
    • 7.4.2 PROVISIONED DEVICE MODEL
      • 7.4.2.1 Growing need for standardization and control in data collection process to support market growth
    • TABLE 31 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR PROVISIONED DEVICE MODELS, BY COUNTRY, 2018-2022 (USD MILLION)
    • TABLE 32 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR PROVISIONED DEVICE MODELS, BY COUNTRY, 2023-2029 (USD MILLION)
    • 7.4.3 HYBRID MODEL
      • 7.4.3.1 Ability of hybrid models to increase balance between standardization and participant preferences to favor growth
    • TABLE 33 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR HYBRID MODELS, BY COUNTRY, 2018-2022 (USD MILLION)
    • TABLE 34 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR HYBRID MODELS, BY COUNTRY, 2023-2029 (USD MILLION)

8 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT

  • 8.1 INTRODUCTION
    • TABLE 35 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2018-2022 (USD MILLION)
    • TABLE 36 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
  • 8.2 ELECTRONIC PATIENT-REPORTED OUTCOMES (EPRO)
    • 8.2.1 GROWING EMPHASIS ON PATIENT-CENTRIC HEALTHCARE TO BOOST MARKET GROWTH
    • TABLE 37 ELECTRONIC PATIENT-REPORTED OUTCOMES (EPRO) MARKET, BY COUNTRY, 2018-2022 (USD MILLION)
    • TABLE 38 ELECTRONIC PATIENT-REPORTED OUTCOMES (EPRO) MARKET, BY COUNTRY, 2023-2029 (USD MILLION)
  • 8.3 ELECTRONIC OBSERVER-REPORTED OUTCOMES (EOBSRO)
    • 8.3.1 GROWING NEED FOR ACCURATE AND RELIABLE DATA COLLECTION TO DRIVE ADOPTION OF EOBSRO SOLUTIONS
    • TABLE 39 ELECTRONIC OBSERVER-REPORTED OUTCOMES (EOBSRO) MARKET, BY COUNTRY, 2018-2022 (USD MILLION)
    • TABLE 40 ELECTRONIC OBSERVER-REPORTED OUTCOMES (EOBSRO) MARKET, BY COUNTRY, 2023-2029 (USD MILLION)
  • 8.4 ELECTRONIC CLINICIAN-REPORTED OUTCOMES (ECLINRO)
    • 8.4.1 INCREASING EFFICACY AND ACCURACY IN CAPTURING CLINICIAN-REPORTED DATA TO PROPEL GROWTH
    • TABLE 41 ELECTRONIC CLINICIAN-REPORTED OUTCOMES (ECLINRO) MARKET, BY COUNTRY, 2018-2022 (USD MILLION)
    • TABLE 42 ELECTRONIC CLINICIAN-REPORTED OUTCOMES (ECLINRO) MARKET, BY COUNTRY, 2023-2029 (USD MILLION)
  • 8.5 ELECTRONIC PERFORMANCE-REPORTED OUTCOME (EPERFO)
    • 8.5.1 INCREASING ACCESSIBILITY AND FLEXIBILITY IN CLINICAL TRIAL SETTINGS TO BOOST MARKET
    • TABLE 43 ELECTRONIC PERFORMANCE-REPORTED OUTCOMES (EPERFO) MARKET, BY COUNTRY, 2018-2022 (USD MILLION)
    • TABLE 44 ELECTRONIC PERFORMANCE-REPORTED OUTCOMES (EPERFO) MARKET, BY COUNTRY, 2023-2029 (USD MILLION)

9 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL

  • 9.1 INTRODUCTION
    • TABLE 45 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2018-2022 (USD MILLION)
    • TABLE 46 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2023-2029 (USD MILLION)
  • 9.2 ON-PREMISE MODEL
    • 9.2.1 OPTIMAL CONTROL ON DEPLOYMENT AND DATA BACKUP TO SUPPORT MARKET UPTAKE
    • TABLE 47 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR ON-PREMISE MODELS, BY REGION, 2018-2022 (USD MILLION)
    • TABLE 48 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR ON-PREMISE MODELS, BY REGION, 2023-2029 (USD MILLION)
  • 9.3 WEB-HOSTED & CLOUD-BASED MODEL
    • 9.3.1 ENHANCED QUALITY OF CLINICAL TRIALS WITH IMPROVED PRODUCTIVITY TO DRIVE MARKET
    • TABLE 49 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEB-HOSTED & CLOUD-BASED MODELS, BY REGION, 2018-2022 (USD MILLION)
    • TABLE 50 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEB-HOSTED & CLOUD-BASED MODELS, BY REGION, 2023-2029 (USD MILLION)
  • 9.4 HYBRID MODEL
    • 9.4.1 ABILITY TO OFFER BALANCED SOLUTIONS USING HYBRID MODEL TO SUPPORT MARKET GROWTH
    • TABLE 51 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR HYBRID MODELS, BY REGION, 2018-2022 (USD MILLION)
    • TABLE 52 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR HYBRID MODELS, BY REGION, 2023-2029 (USD MILLION)

10 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION

  • 10.1 INTRODUCTION
    • TABLE 53 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION)
    • TABLE 54 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
  • 10.2 CLINICAL TRIALS
    • TABLE 55 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION)
    • TABLE 56 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY THERAPEUTIC AREAS, 2023-2029 (USD MILLION)
    • TABLE 57 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY COUNTRY, 2018-2022 (USD MILLION)
    • TABLE 58 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY COUNTRY, 2023-2029 (USD MILLION)
    • 10.2.1 ONCOLOGY
      • 10.2.1.1 Rising incidence of cancer to drive market growth
    • FIGURE 36 US: CANCER INCIDENCE IN MALES, BY TYPE (2022)
    • FIGURE 37 US: CANCER INCIDENCE IN FEMALES, BY TYPE (2022)
    • FIGURE 38 GLOBAL ONCOLOGY CLINICAL TRIALS, 2010-2021 (THOUSAND)
    • TABLE 59 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR ONCOLOGY, BY COUNTRY, 2018-2022 (USD MILLION)
    • TABLE 60 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR ONCOLOGY, BY COUNTRY, 2023-2029 (USD MILLION)
    • 10.2.2 INFECTIOUS DISEASES
      • 10.2.2.1 Growing focus on infectious disease treatment and management to boost market
    • TABLE 61 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2018-2022 (USD MILLION)
    • TABLE 62 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023-2029 (USD MILLION)
    • 10.2.3 NEUROLOGY
      • 10.2.3.1 Increasing investments in R&D and grants for neurological disorders to drive market
    • TABLE 63 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR NEUROLOGY, BY COUNTRY, 2018-2022 (USD MILLION)
    • TABLE 64 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR NEUROLOGY, BY COUNTRY, 2023-2029 (USD MILLION)
    • 10.2.4 METABOLIC DISORDERS
      • 10.2.4.1 Rising diabetes incidence to drive market
    • FIGURE 39 INCREASE IN DIABETES CASES, 2000-2045 (MILLION INDIVIDUALS)
    • TABLE 65 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2018-2022 (USD MILLION)
    • TABLE 66 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2023-2029 (USD MILLION)
    • 10.2.5 IMMUNOLOGY
      • 10.2.5.1 Increasing development of immunology drugs to drive demand for eCOA solutions
    • TABLE 67 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2018-2022 (USD MILLION)
    • TABLE 68 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2023-2029 (USD MILLION)
    • 10.2.6 CARDIOVASCULAR DISEASES
      • 10.2.6.1 Need for efficient and reliable means of collecting patient-reported outcomes in cardiovascular trials to support growth
    • TABLE 69 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2022 (USD MILLION)
    • TABLE 70 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023-2029 (USD MILLION)
    • 10.2.7 RARE DISEASES & GENETIC DISORDERS
      • 10.2.7.1 Growing government support for rare diseases & genetic disorders to boost market
    • TABLE 71 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR RARE DISEASES & GENETIC DISORDERS, BY COUNTRY, 2018-2022 (USD MILLION)
    • TABLE 72 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR RARE DISEASES & GENETIC DISORDERS, BY COUNTRY, 2023-2029 (USD MILLION)
    • 10.2.8 MENTAL HEALTH DISORDERS
      • 10.2.8.1 Growing awareness of mental health disorders to contribute to market growth
    • TABLE 73 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR MENTAL HEALTH DISORDERS, BY COUNTRY, 2018-2022 (USD MILLION)
    • TABLE 74 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR MENTAL HEALTH DISORDERS, BY COUNTRY, 2023-2029 (USD MILLION)
    • 10.2.9 OTHER THERAPEUTIC AREAS
    • TABLE 75 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2018-2022 (USD MILLION)
    • TABLE 76 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023-2029 (USD MILLION)
  • 10.3 OBSERVATIONAL STUDIES & REAL-WORLD EVIDENCE (RWE) GENERATION
    • 10.3.1 GROWING RECOGNITION OF BENEFITS OF REAL-WORLD EVIDENCE GENERATION TO DRIVE DEMAND
    • TABLE 77 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR OBSERVATIONAL STUDIES & REAL-WORLD EVIDENCE (RWE) GENERATION, BY COUNTRY, 2018-2022 (USD MILLION)
    • TABLE 78 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR OBSERVATIONAL STUDIES & REAL-WORLD EVIDENCE (RWE) GENERATION, BY COUNTRY, 2023-2029 (USD MILLION)
  • 10.4 PATIENT MANAGEMENT & REGISTRIES
    • 10.4.1 EVOLVING LANDSCAPE OF PATIENT-CENTRIC HEALTHCARE TO DRIVE SEGMENTAL GROWTH
    • TABLE 79 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR PATIENT MANAGEMENT & REGISTRIES, BY COUNTRY, 2018-2022 (USD MILLION)
    • TABLE 80 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR PATIENT MANAGEMENT & REGISTRIES, BY COUNTRY, 2023-2029 (USD MILLION)
  • 10.5 OTHER APPLICATIONS
    • TABLE 81 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2018-2022 (USD MILLION)
    • TABLE 82 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2029 (USD MILLION)

11 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER

  • 11.1 INTRODUCTION
    • TABLE 83 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION)
    • TABLE 84 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION)
  • 11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 11.2.1 INCREASING R&D EXPENDITURE FOR DRUG DISCOVERY AND DEVELOPMENT TO DRIVE MARKET
    • TABLE 85 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2022 (USD MILLION)
    • TABLE 86 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2029 (USD MILLION)
  • 11.3 CONTRACT RESEARCH ORGANIZATIONS (CROS)
    • 11.3.1 RISING OUTSOURCING OF CLINICAL TRIAL ACTIVITIES TO CROS BY PHARMACEUTICAL COMPANIES TO DRIVE MARKET
    • TABLE 87 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2018-2022 (USD MILLION)
    • TABLE 88 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2023-2029 (USD MILLION)
  • 11.4 GOVERNMENT ORGANIZATIONS
    • 11.4.1 GROWING COLLABORATIONS BETWEEN GOVERNMENT ORGANIZATIONS AND CROS TO PROPEL GROWTH
    • TABLE 89 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR GOVERNMENT ORGANIZATIONS, BY COUNTRY, 2018-2022 (USD MILLION)
    • TABLE 90 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR GOVERNMENT ORGANIZATIONS, BY COUNTRY, 2023-2029 (USD MILLION)
  • 11.5 MEDTECH COMPANIES
    • 11.5.1 GROWING UTILIZATION OF CLINICAL DATA SOFTWARE SOLUTIONS FOR MEDICAL DEVICE TRIALS TO FUEL GROWTH
    • TABLE 91 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR MEDTECH COMPANIES, BY COUNTRY, 2018-2022 (USD MILLION)
    • TABLE 92 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR MEDTECH COMPANIES, BY COUNTRY, 2023-2029 (USD MILLION)
  • 11.6 HOSPITALS & HEALTHCARE PROVIDERS
    • 11.6.1 INCREASING IT BUDGETS TO STREAMLINE PATIENT DATABASES TO PROPEL MARKET GROWTH
    • TABLE 93 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR HOSPITALS & HEALTHCARE PROVIDERS, BY COUNTRY, 2018-2022 (USD MILLION)
    • TABLE 94 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR HOSPITALS & HEALTHCARE PROVIDERS, BY COUNTRY, 2023-2029 (USD MILLION)
  • 11.7 ACADEMIC & RESEARCH INSTITUTES
    • 11.7.1 FAVORABLE GOVERNMENT SUPPORT FOR CLINICAL RESEARCH TO SUPPORT MARKET GROWTH
    • TABLE 95 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2022 (USD MILLION)
    • TABLE 96 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2029 (USD MILLION)
  • 11.8 CONSULTING SERVICE COMPANIES
    • 11.8.1 GROWING COLLABORATIONS BETWEEN CONSULTANCY FIRMS AND PHARMA & BIOTECH COMPANIES TO DRIVE MARKET
    • TABLE 97 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CONSULTING SERVICE COMPANIES, BY COUNTRY, 2018-2022 (USD MILLION)
    • TABLE 98 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CONSULTING SERVICE COMPANIES, BY COUNTRY, 2023-2029 (USD MILLION)

12 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY REGION

  • 12.1 INTRODUCTION
    • TABLE 99 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY REGION, 2018-2022 (USD MILLION)
    • TABLE 100 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY REGION, 2023-2029 (USD MILLION)
  • 12.2 NORTH AMERICA
    • FIGURE 40 NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET SNAPSHOT
    • TABLE 101 NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COUNTRY, 2018-2022 (USD MILLION)
    • TABLE 102 NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 103 NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION)
    • TABLE 104 NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION)
    • TABLE 105 NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2018-2022 (USD MILLION)
    • TABLE 106 NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2023-2029 (USD MILLION)
    • TABLE 107 NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2018-2022 (USD MILLION)
    • TABLE 108 NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 109 NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2018-2022 (USD MILLION)
    • TABLE 110 NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2023-2029 (USD MILLION)
    • TABLE 111 NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION)
    • TABLE 112 NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 113 NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION)
    • TABLE 114 NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION)
    • TABLE 115 NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION)
    • TABLE 116 NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION)
    • 12.2.1 NORTH AMERICA: RECESSION IMPACT
    • 12.2.2 US
      • 12.2.2.1 Rising government funding for pharmaceutical R&D to drive market
    • FIGURE 41 DISTRIBUTION OF R&D COMPANIES, BY COUNTRY/REGION (2021 VS. 2022)
    • TABLE 117 US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION)
    • TABLE 118 US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION)
    • TABLE 119 US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2018-2022 (USD MILLION)
    • TABLE 120 US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2023-2029 (USD MILLION)
    • TABLE 121 US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2018-2022 (USD MILLION)
    • TABLE 122 US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 123 US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2018-2022 (USD MILLION)
    • TABLE 124 US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2023-2029 (USD MILLION)
    • TABLE 125 US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION)
    • TABLE 126 US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 127 US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION)
    • TABLE 128 US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION)
    • TABLE 129 US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION)
    • TABLE 130 US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION)
    • 12.2.3 CANADA
      • 12.2.3.1 Increasing number of clinical trials to support market growth
    • TABLE 131 CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION)
    • TABLE 132 CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION)
    • TABLE 133 CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2018-2022 (USD MILLION)
    • TABLE 134 CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2023-2029 (USD MILLION)
    • TABLE 135 CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2018-2022 (USD MILLION)
    • TABLE 136 CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 137 CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2018-2022 (USD MILLION)
    • TABLE 138 CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2023-2029 (USD MILLION)
    • TABLE 139 CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION)
    • TABLE 140 CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 141 CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION)
    • TABLE 142 CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION)
    • TABLE 143 CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION)
    • TABLE 144 CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION)
  • 12.3 EUROPE
    • TABLE 145 EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COUNTRY, 2018-2022 (USD MILLION)
    • TABLE 146 EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 147 EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION)
    • TABLE 148 EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION)
    • TABLE 149 EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2018-2022 (USD MILLION)
    • TABLE 150 EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2023-2029 (USD MILLION)
    • TABLE 151 EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2018-2022 (USD MILLION)
    • TABLE 152 EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 153 EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2018-2022 (USD MILLION)
    • TABLE 154 EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2023-2029 (USD MILLION)
    • TABLE 155 EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION)
    • TABLE 156 EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 157 EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION)
    • TABLE 158 EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION)
    • TABLE 159 EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION)
    • TABLE 160 EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION)
    • 12.3.1 EUROPE: RECESSION IMPACT
    • 12.3.2 GERMANY
      • 12.3.2.1 Increase in R&D expenditure and clinical trials to boost market growth
    • TABLE 161 GERMANY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION)
    • TABLE 162 GERMANY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION)
    • TABLE 163 GERMANY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2018-2022 (USD MILLION)
    • TABLE 164 GERMANY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2023-2029 (USD MILLION)
    • TABLE 165 GERMANY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2018-2022 (USD MILLION)
    • TABLE 166 GERMANY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 167 GERMANY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2018-2022 (USD MILLION)
    • TABLE 168 GERMANY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2023-2029 (USD MILLION)
    • TABLE 169 GERMANY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION)
    • TABLE 170 GERMANY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 171 GERMANY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION)
    • TABLE 172 GERMANY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION)
    • TABLE 173 GERMANY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION)
    • TABLE 174 GERMANY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION)
    • 12.3.3 UK
      • 12.3.3.1 Growing investments in drug discovery services to favor market growth
    • TABLE 175 UK: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION)
    • TABLE 176 UK: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION)
    • TABLE 177 UK: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2018-2022 (USD MILLION)
    • TABLE 178 UK: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2023-2029 (USD MILLION)
    • TABLE 179 UK: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2018-2022 (USD MILLION)
    • TABLE 180 UK: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 181 UK: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2018-2022 (USD MILLION)
    • TABLE 182 UK: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2023-2029 (USD MILLION)
    • TABLE 183 UK: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION)
    • TABLE 184 UK: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 185 UK: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION)
    • TABLE 186 UK: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION)
    • TABLE 187 UK: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION)
    • TABLE 188 UK: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION)
    • 12.3.4 FRANCE
      • 12.3.4.1 Growing R&D pipeline for oncology trials to drive market
    • TABLE 189 FRANCE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION)
    • TABLE 190 FRANCE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION)
    • TABLE 191 FRANCE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2018-2022 (USD MILLION)
    • TABLE 192 FRANCE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2023-2029 (USD MILLION)
    • TABLE 193 FRANCE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2018-2022 (USD MILLION)
    • TABLE 194 FRANCE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 195 FRANCE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2018-2022 (USD MILLION)
    • TABLE 196 FRANCE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2023-2029 (USD MILLION)
    • TABLE 197 FRANCE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION)
    • TABLE 198 FRANCE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 199 FRANCE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION)
    • TABLE 200 FRANCE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION)
    • TABLE 201 FRANCE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION)
    • TABLE 202 FRANCE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION)
    • 12.3.5 ITALY
      • 12.3.5.1 Increasing government funds and favorable regulatory scenarios to fuel uptake
    • TABLE 203 ITALY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION)
    • TABLE 204 ITALY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION)
    • TABLE 205 ITALY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2018-2022 (USD MILLION)
    • TABLE 206 ITALY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2023-2029 (USD MILLION)
    • TABLE 207 ITALY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2018-2022 (USD MILLION)
    • TABLE 208 ITALY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 209 ITALY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2018-2022 (USD MILLION)
    • TABLE 210 ITALY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2023-2029 (USD MILLION)
    • TABLE 211 ITALY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION)
    • TABLE 212 ITALY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 213 ITALY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION)
    • TABLE 214 ITALY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION)
    • TABLE 215 ITALY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION)
    • TABLE 216 ITALY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION)
    • 12.3.6 REST OF EUROPE
    • TABLE 217 REST OF EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION)
    • TABLE 218 REST OF EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION)
    • TABLE 219 REST OF EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2018-2022 (USD MILLION)
    • TABLE 220 REST OF EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2023-2029 (USD MILLION)
    • TABLE 221 REST OF EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2018-2022 (USD MILLION)
    • TABLE 222 REST OF EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 223 REST OF EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2018-2022 (USD MILLION)
    • TABLE 224 REST OF EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2023-2029 (USD MILLION)
    • TABLE 225 REST OF EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION)
    • TABLE 226 REST OF EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 227 REST OF EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION)
    • TABLE 228 REST OF EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION)
    • TABLE 229 REST OF EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION)
    • TABLE 230 REST OF EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION)
  • 12.4 ASIA PACIFIC
    • FIGURE 42 ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET SNAPSHOT
    • TABLE 231 ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COUNTRY, 2018-2022 (USD MILLION)
    • TABLE 232 ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COUNTRY, 2023-2029 (USD MILLION)
    • TABLE 233 ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION)
    • TABLE 234 ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION)
    • TABLE 235 ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2018-2022 (USD MILLION)
    • TABLE 236 ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2023-2029 (USD MILLION)
    • TABLE 237 ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2018-2022 (USD MILLION)
    • TABLE 238 ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 239 ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2018-2022 (USD MILLION)
    • TABLE 240 ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2023-2029 (USD MILLION)
    • TABLE 241 ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION)
    • TABLE 242 ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 243 ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION)
    • TABLE 244 ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION)
    • TABLE 245 ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION)
    • TABLE 246 ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION)
    • 12.4.1 ASIA PACIFIC: RECESSION IMPACT
    • 12.4.2 JAPAN
      • 12.4.2.1 Established clinical trial infrastructure and increase in funds for R&D to support growth
    • TABLE 247 JAPAN: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION)
    • TABLE 248 JAPAN: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION)
    • TABLE 249 JAPAN: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2018-2022 (USD MILLION)
    • TABLE 250 JAPAN: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2023-2029 (USD MILLION)
    • TABLE 251 JAPAN: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2018-2022 (USD MILLION)
    • TABLE 252 JAPAN: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 253 JAPAN: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2018-2022 (USD MILLION)
    • TABLE 254 JAPAN: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2023-2029 (USD MILLION)
    • TABLE 255 JAPAN: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION)
    • TABLE 256 JAPAN: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 257 JAPAN: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION)
    • TABLE 258 JAPAN: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION)
    • TABLE 259 JAPAN: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION)
    • TABLE 260 JAPAN: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION)
    • 12.4.3 CHINA
      • 12.4.3.1 Low cost of clinical trials and large pharmaceutical R&D base to drive market
    • TABLE 261 CHINA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION)
    • TABLE 262 CHINA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION)
    • TABLE 263 CHINA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2018-2022 (USD MILLION)
    • TABLE 264 CHINA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2023-2029 (USD MILLION)
    • TABLE 265 CHINA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2018-2022 (USD MILLION)
    • TABLE 266 CHINA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 267 CHINA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2018-2022 (USD MILLION)
    • TABLE 268 CHINA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2023-2029 (USD MILLION)
    • TABLE 269 CHINA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION)
    • TABLE 270 CHINA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 271 CHINA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION)
    • TABLE 272 CHINA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION)
    • TABLE 273 CHINA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION)
    • TABLE 274 CHINA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION)
    • 12.4.4 INDIA
      • 12.4.4.1 Growing pharmaceutical industry to fuel uptake of eCOA solutions
    • TABLE 275 INDIA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION)
    • TABLE 276 INDIA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION)
    • TABLE 277 INDIA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2018-2022 (USD MILLION)
    • TABLE 278 INDIA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2023-2029 (USD MILLION)
    • TABLE 279 INDIA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2018-2022 (USD MILLION)
    • TABLE 280 INDIA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 281 INDIA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2018-2022 (USD MILLION)
    • TABLE 282 INDIA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2023-2029 (USD MILLION)
    • TABLE 283 INDIA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION)
    • TABLE 284 INDIA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 285 INDIA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION)
    • TABLE 286 INDIA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION)
    • TABLE 287 INDIA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION)
    • TABLE 288 INDIA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION)
    • 12.4.5 REST OF ASIA PACIFIC
    • TABLE 289 REST OF ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION)
    • TABLE 290 REST OF ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION)
    • TABLE 291 REST OF ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2018-2022 (USD MILLION)
    • TABLE 292 REST OF ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2023-2029 (USD MILLION)
    • TABLE 293 REST OF ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2018-2022 (USD MILLION)
    • TABLE 294 REST OF ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 295 REST OF ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2018-2022 (USD MILLION)
    • TABLE 296 REST OF ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2023-2029 (USD MILLION)
    • TABLE 297 REST OF ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION)
    • TABLE 298 REST OF ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 299 REST OF ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION)
    • TABLE 300 REST OF ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION)
    • TABLE 301 REST OF ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION)
    • TABLE 302 REST OF ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION)
  • 12.5 LATIN AMERICA
    • 12.5.1 LARGE POOL OF PHARMACEUTICAL COMPANIES TO FAVOR MARKET GROWTH
    • TABLE 303 LATIN AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION)
    • TABLE 304 LATIN AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION)
    • TABLE 305 LATIN AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2018-2022 (USD MILLION)
    • TABLE 306 LATIN AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2023-2029 (USD MILLION)
    • TABLE 307 LATIN AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2018-2022 (USD MILLION)
    • TABLE 308 LATIN AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 309 LATIN AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2018-2022 (USD MILLION)
    • TABLE 310 LATIN AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2023-2029 (USD MILLION)
    • TABLE 311 LATIN AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION)
    • TABLE 312 LATIN AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 313 LATIN AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION)
    • TABLE 314 LATIN AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION)
    • TABLE 315 LATIN AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION)
    • TABLE 316 LATIN AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION)
    • 12.5.2 LATIN AMERICA: RECESSION IMPACT
  • 12.6 MIDDLE EAST & AFRICA
    • TABLE 317 MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY REGION, 2018-2022 (USD MILLION)
    • TABLE 318 MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY REGION, 2023-2029 (USD MILLION)
    • TABLE 319 MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION)
    • TABLE 320 MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION)
    • TABLE 321 MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2018-2022 (USD MILLION)
    • TABLE 322 MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2023-2029 (USD MILLION)
    • TABLE 323 MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2018-2022 (USD MILLION)
    • TABLE 324 MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 325 MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2018-2022 (USD MILLION)
    • TABLE 326 MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2023-2029 (USD MILLION)
    • TABLE 327 MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION)
    • TABLE 328 MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 329 MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION)
    • TABLE 330 MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION)
    • TABLE 331 MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION)
    • TABLE 332 MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION)
    • 12.6.1 MIDDLE EAST & AFRICA: RECESSION IMPACT
    • 12.6.2 GCC COUNTRIES
      • 12.6.2.1 Increase in healthcare investments to support market growth
    • TABLE 333 GCC COUNTRIES: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION)
    • TABLE 334 GCC COUNTRIES: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION)
    • TABLE 335 GCC COUNTRIES: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2018-2022 (USD MILLION)
    • TABLE 336 GCC COUNTRIES: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2023-2029 (USD MILLION)
    • TABLE 337 GCC COUNTRIES: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2018-2022 (USD MILLION)
    • TABLE 338 GCC COUNTRIES: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 339 GCC COUNTRIES: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2018-2022 (USD MILLION)
    • TABLE 340 GCC COUNTRIES: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2023-2029 (USD MILLION)
    • TABLE 341 GCC COUNTRIES: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION)
    • TABLE 342 GCC COUNTRIES: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 343 GCC COUNTRIES: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION)
    • TABLE 344 GCC COUNTRIES: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION)
    • TABLE 345 GCC COUNTRIES: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION)
    • TABLE 346 GCC COUNTRIES: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION)
    • 12.6.3 REST OF MIDDLE EAST & AFRICA
    • TABLE 347 REST OF MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION)
    • TABLE 348 REST OF MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION)
    • TABLE 349 REST OF MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2018-2022 (USD MILLION)
    • TABLE 350 REST OF MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2023-2029 (USD MILLION)
    • TABLE 351 REST OF MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2018-2022 (USD MILLION)
    • TABLE 352 REST OF MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2023-2029 (USD MILLION)
    • TABLE 353 REST OF MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2018-2022 (USD MILLION)
    • TABLE 354 REST OF MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2023-2029 (USD MILLION)
    • TABLE 355 REST OF MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION)
    • TABLE 356 REST OF MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION)
    • TABLE 357 REST OF MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION)
    • TABLE 358 REST OF MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION)
    • TABLE 359 REST OF MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION)
    • TABLE 360 REST OF MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION)

13 COMPETITIVE LANDSCAPE

  • 13.1 OVERVIEW
  • 13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • TABLE 361 OVERVIEW OF STRATEGIES DEPLOYED BY KEY ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET VENDORS
  • 13.3 REVENUE ANALYSIS
    • FIGURE 43 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: REVENUE ANALYSIS OF KEY PLAYERS (2018-2022)
  • 13.4 MARKET SHARE ANALYSIS
    • FIGURE 44 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: MARKET SHARE ANALYSIS (2023)
    • TABLE 362 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: DEGREE OF COMPETITION
  • 13.5 BRAND/SOFTWARE COMPARATIVE ANALYSIS
    • 13.5.1 MEDIDATA (US)
    • 13.5.2 IQVIA (US)
    • 13.5.3 ICON PLC (IRELAND)
    • 13.5.4 SIGNANT HEALTH (US)
    • 13.5.5 CLARIO (US)
  • 13.6 VALUATION AND FINANCIAL METRICS OF ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS VENDORS
    • FIGURE 45 EV/EBITDA OF KEY VENDORS
    • FIGURE 46 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • 13.7 COMPANY EVALUATION MATRIX: KEY PLAYERS
    • 13.7.1 STARS
    • 13.7.2 EMERGING LEADERS
    • 13.7.3 PERVASIVE PLAYERS
    • 13.7.4 PARTICIPANTS
    • FIGURE 47 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
    • 13.7.5 COMPANY FOOTPRINT ANALYSIS
    • FIGURE 48 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: COMPANY FOOTPRINT
    • TABLE 363 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: COMPONENT FOOTPRINT
    • TABLE 364 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: DEPLOYMENT MODEL FOOTPRINT
    • TABLE 365 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: END-USER FOOTPRINT
    • TABLE 366 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: REGIONAL FOOTPRINT
  • 13.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES
    • 13.8.1 PROGRESSIVE COMPANIES
    • 13.8.2 DYNAMIC COMPANIES
    • 13.8.3 RESPONSIVE COMPANIES
    • 13.8.4 STARTING BLOCKS
    • FIGURE 49 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
    • 13.8.5 COMPETITIVE BENCHMARKING
    • TABLE 367 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET: DETAILED LIST OF KEY SMES/STARTUPS
    • TABLE 368 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS (STARTUPS/SMES)
  • 13.9 COMPETITIVE SCENARIO
    • TABLE 369 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: PRODUCT LAUNCHES & UPGRADES, JANUARY 2021-NOVEMBER 2023
    • TABLE 370 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: DEALS, JANUARY 2021-NOVEMBER 2023

14 COMPANY PROFILES

  • (Business overview, Products/Services/Solutions offered, Recent Developments, MNM view)**
  • 14.1 KEY PLAYERS
    • 14.1.1 MEDIDATA (A DASSAULT SYSTEMES COMPANY)
    • TABLE 371 MEDIDATA: COMPANY OVERVIEW
    • FIGURE 50 DASSAULT SYSTEMES: COMPANY SNAPSHOT (2022)
    • TABLE 372 MEDIDATA: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 373 MEDIDATA: PRODUCT/SERVICE LAUNCHES
    • TABLE 374 MEDIDATA: DEALS
    • 14.1.2 IQVIA
    • TABLE 375 IQVIA: COMPANY OVERVIEW
    • FIGURE 51 IQVIA: COMPANY SNAPSHOT (2022)
    • TABLE 376 IQVIA: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • 14.1.3 SIGNANT HEALTH
    • TABLE 377 SIGNANT HEALTH: COMPANY OVERVIEW
    • TABLE 378 SIGNANT HEALTH: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 379 SIGNANT HEALTH: PRODUCT/SERVICE LAUNCHES & UPGRADES
    • TABLE 380 SIGNANT HEALTH: DEALS
    • 14.1.4 CLARIO
    • TABLE 381 CLARIO: COMPANY OVERVIEW
    • TABLE 382 CLARIO: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 383 CLARIO: DEALS
    • 14.1.5 ICON PLC
    • TABLE 384 ICON PLC: COMPANY OVERVIEW
    • FIGURE 52 ICON PLC: COMPANY SNAPSHOT (2022)
    • TABLE 385 ICON PLC: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 386 ICON PLC: PRODUCT/SERVICE LAUNCHES
    • TABLE 387 ICON PLC: DEALS
    • 14.1.6 ORACLE CORPORATION
    • TABLE 388 ORACLE CORPORATION: COMPANY OVERVIEW
    • FIGURE 53 ORACLE CORPORATION: COMPANY SNAPSHOT (2022)
    • TABLE 389 ORACLE CORPORATION: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 390 ORACLE CORPORATION: DEALS
    • 14.1.7 MEDABLE INC.
    • TABLE 391 MEDABLE INC.: COMPANY OVERVIEW
    • TABLE 392 MEDABLE INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 393 MEDABLE INC.: PRODUCT/SERVICE LAUNCHES
    • TABLE 394 MEDABLE INC.: DEALS
    • 14.1.8 MERATIVE L.P.
    • TABLE 395 MERATIVE L.P.: COMPANY OVERVIEW
    • TABLE 396 MERATIVE L.P.: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • 14.1.9 PAREXEL INTERNATIONAL (MA) CORPORATION
    • TABLE 397 PAREXEL INTERNATIONAL (MA) CORPORATION: COMPANY OVERVIEW
    • TABLE 398 PAREXEL INTERNATIONAL (MA) CORPORATION: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 399 PARAXEL INTERNATIONAL (MA) CORPORATION: EXPANSIONS
    • 14.1.10 CLIMEDO HEALTH GMBH
    • TABLE 400 CLIMEDO HEALTH GMBH: COMPANY OVERVIEW
    • TABLE 401 CLIMEDO HEALTH GMBH: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 402 CLIMEDO HEALTH GMBH: OTHER DEVELOPMENTS
    • 14.1.11 HEALTHENTIA (A PRODUCT OF INNOVATION SPRINT)
    • TABLE 403 INNOVATION SPRINT: COMPANY OVERVIEW
    • TABLE 404 HEALTHENTIA: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • 14.1.12 VEEVA SYSTEMS
    • TABLE 405 VEEVA SYSTEMS: COMPANY OVERVIEW
    • FIGURE 54 VEEVA SYSTEMS: COMPANY SNAPSHOT (2022)
    • TABLE 406 VEEVA SYSTEMS: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 407 VEEVA SYSTEMS: PRODUCT/SERVICE LAUNCHES
    • TABLE 408 VEEVA SYSTEMS: DEALS
    • 14.1.13 ASSISTEK
    • TABLE 409 ASSISTEK: COMPANY OVERVIEW
    • TABLE 410 ASSISTEK: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 411 ASSISTEK: DEALS
    • 14.1.14 CUREBASE INC.
    • TABLE 412 CUREBASE INC.: COMPANY OVERVIEW
    • TABLE 413 CUREBASE INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 414 CUREBASE INC.: OTHER DEVELOPMENTS
    • 14.1.15 CASTOR
    • TABLE 415 CASTOR: COMPANY OVERVIEW
    • TABLE 416 CASTOR: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 417 CASTOR: PRODUCT/SERVICE LAUNCHES
    • TABLE 418 CASTOR: OTHER DEVELOPMENTS
    • 14.1.16 EVIDENTIQ GROUP GMBH
    • TABLE 419 EVIDENTIQ GROUP GMBH: COMPANY OVERVIEW
    • TABLE 420 EVIDENTIQ GROUP GMBH: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • 14.1.17 YPRIME, LLC
    • TABLE 421 YPRIME, LLC: COMPANY OVERVIEW
    • TABLE 422 YPRIME, LLC: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 423 YPRIME, LLC: PRODUCT/SERVICE LAUNCHES
    • TABLE 424 YPRIME, LLC: DEALS
    • 14.1.18 CLINICAL INK
    • TABLE 425 CLINICAL INK: COMPANY OVERVIEW
    • TABLE 426 CLINICAL INK: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 427 CLINICAL INK: PRODUCT/SERVICE LAUNCHES & UPGRADES
    • TABLE 428 CLINICAL INK: DEALS
    • 14.1.19 CLINION
    • TABLE 429 CLINION: COMPANY OVERVIEW
    • TABLE 430 CLINION: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • 14.1.20 KAYENTIS
    • TABLE 431 KAYENTIS: COMPANY OVERVIEW
    • TABLE 432 KAYENTIS: PRODUCTS/SOLUTIONS/SERVICES OFFERED
    • TABLE 433 KAYENTIS: DEALS
    • TABLE 434 KAYENTIS: OTHER DEVELOPMENTS
  • 14.2 OTHER PLAYERS
    • 14.2.1 TRANSPERFECT
    • 14.2.2 OBVIOHEALTH USA, INC.
    • 14.2.3 WCG CLINICAL
    • 14.2.4 CLINCAPTURE
    • 14.2.5 CLOUDBYZ
  • *Details on Business overview, Products/Services/Solutions offered, Recent Developments, MNM view might not be captured in case of unlisted companies.

15 APPENDIX

  • 15.1 DISCUSSION GUIDE
  • 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 15.3 CUSTOMIZATION OPTIONS
  • 15.4 RELATED REPORTS
  • 15.5 AUTHOR DETAILS